BioVentrix (BVXX) investor relations material

Company overview and business model

• Focuses on developing, manufacturing, and commercializing proprietary devices to restore left ventricular function in heart failure patients with reduced ejection fraction (HFrEF).

• Lead product, the Revivent System, is CE-marked in Europe and in pivotal U.S. clinical trials; aims to become the new standard of care for patients with severe anterior wall scarring post-STEMI or ICM.

• Also owns Alginate, a hydrogel-based device for HFrEF patients without anterior scarring, with plans for future clinical development.

• Business model centers on clinical validation, regulatory approval, and targeted commercialization, with initial focus on U.S. and potential expansion to Europe and other markets.

Financial performance and metrics

• Reported net losses of $3.3 million for Q1 2026 and $7.7 million for the year ended December 31, 2025; accumulated deficit of $234.5 million as of March 31, 2026.

• Cash balance of $924,026 as of March 31, 2026; working capital deficit of $14.6 million.

• Research and development expenses increased 451% year-over-year for Q1 2026, reflecting ramp-up of the RELIVE trial.

• Company has historically relied on private equity and convertible debt financings; substantial doubt exists about ability to continue as a going concern without additional capital.

Use of proceeds and capital allocation

• Net proceeds from the IPO will primarily fund the RELIVE clinical trial and associated manufacturing activities (approx. 38% of proceeds).

• Remaining proceeds allocated to working capital, regulatory compliance, IP protection, and general corporate purposes.

• Management retains broad discretion over use of funds; additional capital will be needed for full commercialization and further development.